Show simple item record

Misperceptions About β-Blockers and Diuretics

dc.contributor.authorUbel, Peter A.en_US
dc.contributor.authorJepson, Christopheren_US
dc.contributor.authorAsch, David A.en_US
dc.date.accessioned2010-06-01T22:23:30Z
dc.date.available2010-06-01T22:23:30Z
dc.date.issued2003-12en_US
dc.identifier.citationUbel, Peter A.; Jepson, Christopher; Asch, David A. (2003). "Misperceptions About β-Blockers and Diuretics." Journal of General Internal Medicine 18(12): 977-983. <http://hdl.handle.net/2027.42/75385>en_US
dc.identifier.issn0884-8734en_US
dc.identifier.issn1525-1497en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75385
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14687255&dopt=citationen_US
dc.description.abstractBased on a series of clinical trials showing no difference in the effectiveness or tolerability of most major classes of antihypertensive medications, the Joint National Commission on High Blood Pressure Treatment recommends that physicians prescribe β-blockers or diuretics as initial hypertensive therapy unless there are compelling indications for another type of medication. Nevertheless, many physicians continue to favor more expensive medications like angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers as first line agents. The persistent use of these agents raises questions as to whether physicians perceive ACE inhibitors and calcium channel blockers to be better than β-blockers and diuretics. METHODS:  We surveyed 1,200 primary care physicians in 1997, and another 500 primary care physicians in 2000, and asked them to estimate the relative effectiveness and side effects of 4 classes of medication in treating a hypothetical patient with uncomplicated hypertension: ACE inhibitors, β-blockers, calcium channel blockers, and diuretics. In addition, we asked them to indicate whether they ever provided free samples of hypertension medications to their patients. RESULTS:  Perceptions of the relative effectiveness and side effects of the 4 classes of hypertension medications did not significantly change over the 3 years, nor did prescription recommendations. Physicians perceive that diuretics are less effective at lowering blood pressure than the other 3 classes ( P  < .001). They also perceive that β-blockers are less tolerated than the other 3 classes ( P  < .001). In a multivariate model, perceptions of effectiveness and tolerability displayed significant associations with prescription preference independent of background variables. The only other variable to contribute significantly to the model was provision of free medication samples to patients. CONCLUSIONS:  Despite numerous clinical trials showing no difference in the effectiveness or side-effect profiles of these 4 classes of drugs, most physicians believed that diuretics were less effective and β-blockers were less tolerated than other medications. Moreover, their prescription practices were associated with their provision of free samples provided by pharmaceutical representatives, even after adjusting for other demographic characteristics. Efforts to increase physicians’ prescribing of β-blockers and diuretics may need to be directed at overcoming misunderstandings about the effectiveness and tolerability of these medicines. J GEN INTERN MED 2003;18:977–983.en_US
dc.format.extent124271 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltd.en_US
dc.rights© 2003 by the Society of General Internal Medicineen_US
dc.subject.otherHypertension Treatmenten_US
dc.subject.otherPhysician Surveyen_US
dc.subject.otherPharmaceutical Promotion.en_US
dc.titleMisperceptions About β-Blockers and Diureticsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumReceived from VA Health Services Research & Development Center of Excellence, VA Ann Arbor Healthcare System (PAU), Division of General Internal Medicine, University of Michigan (PAU), and Program for Improving Health Care Decisions, University of Michigan (PAU), Ann Arbor, Mich; Division of General Internal Medicine, University of Pennsylvania School of Medicine (CJ, DAA), Leonard Davis Institute of Health Economics, University of Pennsylvania (DAA), and Center for Health Equity Research and Promotion, Veterans Affairs Medical Center (DAA), Philadelphia, Pa.en_US
dc.identifier.pmid14687255en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75385/1/j.1525-1497.2003.20414.x.pdf
dc.identifier.doi10.1111/j.1525-1497.2003.20414.xen_US
dc.identifier.sourceJournal of General Internal Medicineen_US
dc.identifier.citedreference 1.  Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157: 2413 – 46.en_US
dc.identifier.citedreferenceHansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000; 356: 359 – 65.en_US
dc.identifier.citedreferenceBrown M, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet. 2000; 5: 366 – 72.en_US
dc.identifier.citedreferenceNeaton J, Grimm R, Prineas R, et al. Treatment Mild Hypertension Study: final results. JAMA. 1993; 270: 713 – 24.en_US
dc.identifier.citedreferenceMaterson B, Reda D, Cushman W. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Am J Hypertens. 1995; 8: 189 – 92.en_US
dc.identifier.citedreferenceHannsson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999; 353: 611 – 6.en_US
dc.identifier.citedreferenceCroog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986; 314: 1657 – 64.en_US
dc.identifier.citedreferenceMaterson B, Reda D, Cushman W, et al. Single-drug therapy for hypertension in men: a comparison of six hypertensive agents with placebo. N Engl J Med. 1993; 328: 914 – 21.en_US
dc.identifier.citedreferenceOgihara T, Kuramoto K. Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. Hypertens Res. 2000; 23: 33 – 7.en_US
dc.identifier.citedreferenceManolio T, Cutler J, Furberg C, Psaty B, Whelton P, Applegate W. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995; 155: 829 – 37.en_US
dc.identifier.citedreferenceSiegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? JAMA. 1997; 278: 1745 – 8.en_US
dc.identifier.citedreferenceAvorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982; 73: 4 – 8.en_US
dc.identifier.citedreferenceChren M-M, Landefeld CS. Physicians’ behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994; 271: 684 – 9.en_US
dc.identifier.citedreferenceMoser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998; 279: 1813 – 6.en_US
dc.identifier.citedreferenceWang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertsing, 1985–96. Circulation. 1999; 99: 2055 – 7.en_US
dc.identifier.citedreferenceLurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. 1990; 5: 240 – 3.en_US
dc.identifier.citedreferenceBowman MA. The impact of drug company funding on the content of continuing medical education. Mobius. 1986; 6: 66 – 9.en_US
dc.identifier.citedreferenceBowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988; 8: 13 – 20.en_US
dc.identifier.citedreferenceChew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians’ behavior. J Gen Intern Med. 2000; 15: 478 – 83.en_US
dc.identifier.citedreferenceShaughnessy A, Bucci K. Drug samples and family practice residents. Ann Pharmacother. 1997; 31: 1296 – 1300.en_US
dc.identifier.citedreferenceMorelli D, Koenigsberg M. Sample medication dispensing in a residency practice. J Fam Pract. 1992; 34: 42 – 8.en_US
dc.identifier.citedreferencePeay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988; 26: 1183 – 9.en_US
dc.identifier.citedreferenceCaudill ST, Johnson MS, Rich EC, McKinney PW. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med. 1996; 5: 201 – 6.en_US
dc.identifier.citedreferencePeabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of vignettes, standardized patients, and chart abstraction. A prospective validation study of 3 methods for measuring quality. JAMA. 2000; 283: 1715 – 22.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.